Reframe Daily: Exercise after chemo boosts colon-cancer survival; lung & skin trials extend life + Walking Meditation

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Exercise after chemo helped people with colon cancer stay cancer-free longer; adding nivolumab before surgery raised 5-year survival in resectable lung cancer; taking cemiplimab after surgery lowered the return of high-risk skin cancer; an inhaled GM-CSF treatment helped people with a rare lung disease (aPAP); and a toripalimab plan without cisplatin worked with fewer side effects in nasopharyngeal cancer.  

Christin’s note: Doomscrolling feels good because it drowns out a harsh inner voice—but it leaves a hangover. Meditation isn’t self-improvement (that frame actually feeds the problem); it’s learning to see thoughts clearly and loosen their grip. A simple experiment: try walking meditation. Put attention on the sensations of each step—“left, right, left, right”—and notice when the mind drifts. Walking outside helps, especially if sitting still feels activating. Use this the next time you’re stuck in short-form loops; it’s a gentler, realistic way to create a little space and relief. Watch the video to learn more!

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Weekly personal shares from Christin here →
http://christin.substack.com/

Good news: A simple, coach-guided exercise plan after chemo helped people with colon cancer stay cancer-free longer and likely live longer.

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

Market readiness: 😀😀😀😀 (exercise and coaching programs exist now; this large randomized trial strengthens the case to plug them into standard care)

Good news: A pre-surgery combo of an immune drug (nivolumab) plus chemo helped more people with lung cancer live longer.

Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Market readiness: 😀😀😀😀😀 (already FDA-approved for resectable NSCLC; this adds hard survival evidence to guide use)

Good news: For a stubborn skin cancer (high-risk cutaneous squamous-cell carcinoma), taking cemiplimab after surgery kept cancer from coming back longer.

Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma

Market readiness: 😀😀😀 (phase 3 success; adjuvant use isn’t yet FDA-approved, but this could drive guideline and label updates)

Good news: People with a rare lung disease (autoimmune pulmonary alveolar proteinosis) improved with an inhaled GM-CSF treatment (molgramostim).

Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

Market readiness: 😀😀😀 (positive phase 3 in a defined patient group; regulatory review would be next for U.S. availability)

Good news: For nasopharyngeal cancer, a cisplatin-free plan using toripalimab kept cancer in check as well as the cisplatin plan—and with fewer side effects.

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial

Market readiness: 😀😀😀😀 (toripalimab is on the U.S. market; this regimen could be adopted once guidelines incorporate the new evidence)

Thank you for taking the time to take care of yourself and your loved ones.